MetaLabs' Largest Shareholder Joins KRW 6 Billion Rights Offering... Driving Growth Investments with Responsible Management

MetaLabs is promoting a third-party allotment capital increase worth 6 billion won, targeting a specially related party of its largest shareholder. The company aims to use the funds raised to strengthen its control over subsidiaries and reinforce its foundation for mid- to long-term growth investments.

On June 9, MetaLabs announced via a public disclosure that MetaPharm, a company in a joint ownership relationship with the largest shareholder, will participate in the third-party allotment capital increase. The scheduled payment date is June 17, 2026.

The company explained that this rights offering is structured so that the largest shareholder is directly increasing capital, serving as an example of its commitment to responsible management and trust in the company’s growth strategy.

The funds raised will be used to participate in a third-party allotment capital increase for its subsidiary MetaCare. MetaLabs plans to strengthen its control by increasing its investment in MetaCare. Once the payment is completed, MetaLabs’ stake in MetaCare will rise from the current 37.28% to 51.78%.

MetaCare plans to utilize the funds secured from this capital increase for acquiring shares in other companies. The company’s strategy is to review potential synergies with its existing business during the new investment process and to expand its consolidated revenue and profit base.

A MetaLabs representative stated, “This rights offering, with the direct participation of our largest shareholder, demonstrates both trust in the company’s growth potential and a commitment to responsible management,” adding, “Through the investment structure connecting MetaLabs and MetaCare, we will strengthen our subsidiary control and continue to expand our foundation for mid- to long-term growth.”

The company’s performance is also showing improvement. In the first quarter of this year, MetaLabs’ consolidated revenue reached 30.4 billion won, a 262% increase compared to the same period last year. Operating profit turned positive, reaching 500 million won, as profitability improved by 11.1 percentage points from the same period last year.

The key point of this rights offering is that it underscores the commitment to responsible management through the direct participation of the largest shareholder, while also enabling the expansion of control over MetaCare and securing resources for new investments.

This content was produced with the assistance of AI translation services.